A. Tefferi, P. Guglielmelli, and D. R. Larson, Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis, Blood, vol.124, issue.16, pp.2507-2513, 2014.

R. A. Mesa, C. Li, R. P. Ketterling, G. S. Schroeder, R. A. Knudson et al., Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases, Blood, vol.105, issue.3, pp.973-977, 2005.

C. S. Tam, R. M. Nussenzveig, and U. Popat, The natural history and treatment outcome of blast phase BCR-ABL-myeloproliferative neoplasms, Blood, vol.112, issue.5, pp.1628-1637, 2008.

A. Tefferi, M. Mudireddy, and F. Mannelli, Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts, Leukemia, vol.32, issue.5, pp.1200-1210, 2018.

F. Passamonti, E. Rumi, and L. Arcaini, Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients, Haematologica, vol.93, issue.11, pp.1645-1651, 2008.

A. Tefferi, E. Rumi, and G. Finazzi, Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study, Leukemia, vol.27, issue.9, pp.1874-1881, 2013.

L. Mollard, A. Chauveau, and F. Boyer-perrard, Outcome of Ph negative myeloproliferative neoplasms transforming to accelerated or leukemic phase, Leuk Lymphoma, vol.59, issue.12, pp.2812-2820, 2018.

D. Cuthbert and B. L. Stein, Therapy-associated leukemic transformation in myeloproliferative neoplasms -What do we know?, Best Pract Res Clin Haematol, vol.32, issue.1, pp.65-73, 2019.

G. Finazzi, V. Caruso, and R. Marchioli, Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study, ECLAP Investigators, vol.105, pp.2664-2670, 2005.

N. Gangat, A. P. Wolanskyj, and R. F. Mcclure, Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients, Leukemia, vol.21, issue.2, pp.270-276, 2007.

A. Alvarez-larrán, A. Senín, and C. Fernández-rodríguez, Impact of genotype on leukaemic transformation in polycythaemia vera and essential thrombocythaemia, Br J Haematol, vol.178, issue.5, pp.764-771, 2017.

J. Grinfeld, J. Nangalia, and E. J. Baxter, Classification and Personalized Prognosis in Myeloproliferative Neoplasms, N Engl J Med, vol.379, issue.15, pp.1416-1430, 2018.

A. Tefferi, P. Guglielmelli, and T. L. Lasho, Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera, Br J Haematol, vol.189, issue.2, pp.291-302, 2020.

A. Pardanani, T. Lasho, C. Finke, S. T. Oh, J. Gotlib et al., LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations, Leukemia, vol.24, issue.10, pp.1713-1718, 2010.

A. Harutyunyan, T. Klampfl, M. Cazzola, and R. Kralovics, p53 lesions in leukemic transformation, N Engl J Med, vol.364, issue.5, pp.488-490, 2011.

F. Courtier, N. Carbuccia, and S. Garnier, Genomic analysis of myeloproliferative neoplasms in chronic and acute phases, Haematologica, vol.102, issue.1, pp.11-14, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01789589

T. L. Lasho, M. Mudireddy, and C. M. Finke, Targeted next-generation sequencing in blast phase myeloproliferative neoplasms, Blood Adv, vol.2, issue.4, pp.370-380, 2018.

R. Rampal, J. Ahn, A. -. Wahab, and O. , Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms, Proc Natl Acad Sci, vol.111, issue.50, pp.5401-5410, 2014.

P. Lundberg, A. Karow, and R. Nienhold, Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms, Blood, vol.123, issue.14, pp.2220-2228, 2014.

P. A. Beer, F. Delhommeau, and J. P. Lecouédic, Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm, Blood, vol.115, issue.14, pp.2891-2900, 2010.

S. Richards, N. Aziz, and S. Bale, ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology, Genet Med, vol.17, issue.5, pp.405-424, 2015.

M. M. Li, M. Datto, and E. J. Duncavage, Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, J Mol Diagn, vol.19, issue.1, pp.4-23, 2017.

M. Tenenhaus, La régression PLS, théorie et pratique. Paris: Editions Technip, 1998.

L. Cao, K. Martin, P. G. Robert-granié, C. Besse, and P. , Sparse canonical methods for biological data integration: application to a cross-platform study, BMC Bioinformatics, vol.10, issue.1, p.34, 2009.
URL : https://hal.archives-ouvertes.fr/hal-00323818

J. N. Weinstein, T. G. Myers, O. Connor, and P. M. , An information-intensive approach to the molecular pharmacology of cancer, Science, vol.275, issue.5298, pp.343-349, 1997.

M. B. Eisen, P. T. Spellman, P. O. Brown, and D. Botstein, Cluster analysis and display of genome-wide expression patterns, Proc Natl Acad Sci, vol.95, issue.25, pp.14863-14868, 1998.

K. Zoi and N. Cross, Genomics of Myeloproliferative Neoplasms, J Clin Oncol, vol.35, issue.9, pp.947-954, 2017.

C. J. Mcnamara, T. Panzarella, and J. A. Kennedy, The mutational landscape of accelerated-and blast-phase myeloproliferative neoplasms impacts patient outcomes, Blood Adv, vol.2, issue.20, pp.2658-2671, 2018.

T. Barbui, J. Thiele, and F. Passamonti, Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study, J Clin Oncol, vol.29, issue.23, pp.3179-3184, 2011.

G. Jeryczynski, J. Thiele, and B. Gisslinger, Pre-fibrotic/early primary myelofibrosis vs. WHO-defined essential thrombocythemia: The impact of minor clinical diagnostic criteria on the outcome of the disease, Am J Hematol, vol.92, issue.9, pp.885-891, 2017.

M. H. Bailey, C. Tokheim, and E. Porta-pardo, Cancer Genome Atlas Research Network. Comprehensive Characterization of Cancer Driver Genes and Mutations, Cell, vol.174, issue.4, pp.371-385, 2018.

L. Paz, D. Mansier, O. Riou, and J. , Positive impact of molecular analysis on prognostic scores in essential thrombocythemia: a single center prospective cohort experience, Haematologica, vol.104, issue.4, pp.134-137, 2019.
URL : https://hal.archives-ouvertes.fr/inserm-02516720

M. Gerritsen, G. Yi, and E. Tijchon, RUNX1 mutations enhance self-renewal and block granulocytic differentiation in human in vitro models and primary AMLs, Blood Adv, vol.3, issue.3, pp.320-332, 2019.

R. Agarwal, P. Blombery, and M. Mcbean, Clinicopathological differences exist between CALR-and JAK2-mutated myeloproliferative neoplasms despite a similar molecular landscape: data from targeted next-generation sequencing in the diagnostic laboratory, Ann Hematol, vol.96, issue.5, pp.725-732, 2017.

I. Plo, M. Nakatake, and L. Malivert, JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders, Blood, vol.112, issue.4, pp.1402-1412, 2008.

B. Kubesova, S. Pavlova, and J. Malcikova, Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status, Leukemia, vol.32, issue.2, pp.450-461, 2018.

T. N. Wong, G. Ramsingh, and A. L. Young, Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia, Nature, vol.518, issue.7540, pp.552-555, 2015.

L. Arranz, A. Sánchez-aguilera, and D. Martín-pérez, Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms, Nature, vol.512, issue.7512, pp.78-81, 2014.

J. Kiladjian, S. Chevret, C. Dosquet, C. Chomienne, and J. Rain, Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980, J Clin Oncol, vol.29, issue.29, pp.3907-3913, 2011.

M. Brecqueville, J. Rey, and F. Bertucci, Mutation analysis of ASXL1, Genes Chromosomes Cancer, vol.51, issue.8, pp.743-755, 2012.

A. Tefferi, A. Pardanani, and K. Lim, TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis, Leukemia, vol.23, issue.5, pp.905-911, 2009.

A. Tefferi, T. L. Lasho, and P. Guglielmelli, Targeted deep sequencing in polycythemia vera and essential thrombocythemia, Blood Adv, vol.1, issue.1, pp.21-30, 2016.

A. Senín, C. Fernández-rodríguez, and B. Bellosillo, Non-driver mutations in patients with JAK2V617F-mutated polycythemia vera or essential thrombocythemia with long-term molecular follow-up, Ann Hematol, vol.97, issue.3, pp.443-451, 2018.

G. Venton, F. Courtier, and A. Charbonnier, Impact of gene mutations on treatment response and prognosis of acute myeloid leukemia secondary to myeloproliferative neoplasms, Am J Hematol, vol.93, issue.3, pp.330-338, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01788547

M. Ruggiu, B. Cassinat, and J. Kiladjian, Should transplantation still be considered for Ph1-negative myeloproliferative neoplasms in transformation?, Biol Blood Marrow Transplant, vol.26, issue.6, pp.1160-1170, 2020.

S. Zhang, R. Rampal, and T. Manshouri, Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome, Blood, vol.119, pp.4480-4485, 2012.